middle.news
PYC Therapeutics Advances Four Genetic Disease Programs, Eyes Transformative 2025
9:25am on Wednesday 29th of January, 2025 AEDT
•
Biotechnology
Read Story
PYC Therapeutics Advances Four Genetic Disease Programs, Eyes Transformative 2025
9:25am on Wednesday 29th of January, 2025 AEDT
Key Points
Phase 1/2 clinical data presented for Retinitis Pigmentosa type 11 showing patient improvement
FDA grants Orphan Drug and Rare Pediatric Disease designations for RP11 candidate
First dosing completed in Autosomal Dominant Optic Atrophy clinical trial
Pre-clinical studies completed and regulatory submission made for Polycystic Kidney Disease program
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PYC Therapeutics (ASX:PYC)
OPEN ARTICLE